Hargreaves Lansdown investors are buying Synairgen shares. Should I buy too?

Synairgen shares have been volatile. But should I buy now? This Fool takes a closer look at the company’s recent announcement.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been bullish on Synairgen (LSE: SNG) shares for sometime. But the stock has been volatile. So far in 2021 the share price is up only 5% but during the past 12 months it has increased by over 280%. Of course, past performance isn’t an indication of future returns.

Even Hargreaves Lansdown investors have turned positive on Synairgen shares. The company was one of the top 10 most purchased stocks last week on the platform.

The AIM-listed firm recently came out with an announcement, which I thought was very encouraging. I’m still bullish on the stock and would buy it in my portfolio.

The announcement

So, last week, Synairgen released a statement saying that its in vitro studies showed that its treatment is effective against key Covid-19 variants. I’m not surprised the stock jumped on this news.

As a quick reminder, the company developed SNG001, which is a treatment for Covid-19. It’s worth adding here that this is not a vaccine. This is used to treat those who are already infected with the coronavirus. So far, the clinical trials of SNG001 have been successful.

But what does this new announcement mean? Well, it’s certainly positive news for Synairgen shares.

Studies were conducted at labs in the Netherlands, confirming that SNG001 “potently reduced”  the coronavirus to “undetectable levels” in cells that were infected with the “Wuhan-like” strain as well as the UK/Kent and South African variants.

My view

I’ve previously commented that I think Synairgen shares have bags of potential. And I think this announcement demonstrates it.

Clearly the emerging Covid-19 variants are of huge concern. They pose a threat to the global economy returning to any kind of normality. While the current vaccines are proving to be effective, I don’t think this is enough. They may not work against future coronavirus variants. It’s great to see that the data confirms that “SNG001 is a broad-spectrum antiviral product”.

What I like about Synairgen is that SNG001 could play a key role in combating seasonal variants and other respiratory diseases. I also agree with CEO Richard Marsden’s comments that it’s pleasing “to see initiatives being put in place to accelerate and support development of antiviral therapeutics as a backstop for patients who are admitted to hospital”.

It means that the company’s products could be at the forefront of treating Covid-19. In my view, it also places Synairgen on the radar as a potential takeover target by a larger competitor once the pandemic is over. The company will start dosing patients at trial sites in India as part of its SNG001 Phase III study imminently.

Risks

Syanirgen shares come with a lot of risk. I only have to look at the stock price chart to see that investors are in for a volatile ride. I’d only invest what I could afford to lose.

The company hasn’t generated any revenue yet and so it’s loss-making. I expect this to be the case for sometime because Synairgen is still conducting clinical trials for SNG001. There’s no guarantee this will be successful, so investors may need to brace themselves.

But I’m aware of the risks involved with Synairgen shares. I think this announcement is positive news and could push the stock higher.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »